Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | 10% owner | February 08, 2021 | February 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date February 08, 2021 · Filed February 10, 2021
Jointly reported with H&S INVESTMENTS I LP, H&S VENTURES LLC, SCHULMAN MICHAEL, SAMUELI HENRY
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,425,998 |
Reported balance
After 2021-02-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-02-08 · Conversion · Acquired 4,361,835 · Balance 4,425,998 F1: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F2: The shares are held by H&S Investments I, L.P ("H&S Investments"), H&S Ventures, LLC ("H&S Ventures"), its general partner, and Michael Shulman, manager of H&S Ventures may be deemed to have voting and dispositive power with respect to the shares held. Henry Samueli and Susan Samueli are the non-managing members of H&S Ventures and each have the right to replace the managing member of H&S Ventures at any time. Henry Samueli and Susan Samueli may be deemed to beneficially own any shares directly owned by H&S Investments. |
| Series AA Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-08 · Conversion · Disposed 209,368,245 · Balance 0 F1: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F2: The shares are held by H&S Investments I, L.P ("H&S Investments"), H&S Ventures, LLC ("H&S Ventures"), its general partner, and Michael Shulman, manager of H&S Ventures may be deemed to have voting and dispositive power with respect to the shares held. Henry Samueli and Susan Samueli are the non-managing members of H&S Ventures and each have the right to replace the managing member of H&S Ventures at any time. Henry Samueli and Susan Samueli may be deemed to beneficially own any shares directly owned by H&S Investments. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date.
F2: The shares are held by H&S Investments I, L.P ("H&S Investments"), H&S Ventures, LLC ("H&S Ventures"), its general partner, and Michael Shulman, manager of H&S Ventures may be deemed to have voting and dispositive power with respect to the shares held. Henry Samueli and Susan Samueli are the non-managing members of H&S Ventures and each have the right to replace the managing member of H&S Ventures at any time. Henry Samueli and Susan Samueli may be deemed to beneficially own any shares directly owned by H&S Investments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 23:44 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | ConversionSeries AA Convertible Preferred Stock · Derivative | 209,368,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009411 · doc4.xml · derivative · entry 2 H&S INVESTMENTS I LP · CIK 0001219243 · 10% owner H&S VENTURES LLC · CIK 0001219242 · 10% owner SCHULMAN MICHAEL · CIK 0001219244 · 10% owner SAMUELI HENRY · CIK 0001201633 · 10% owner SAMUELI SUSAN · CIK 0001219241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,361,835 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held by H&S Investments I, L.P ("H&S Investments"), H&S Ventures, LLC ("H&S Ventures"), its general partner, and Michael Shulman, manager of H&S Ventures may be deemed to have voting and dispositive power with respect to the shares held. Henry Samueli and Susan Samueli are the non-managing members of H&S Ventures and each have the right to replace the managing member of H&S Ventures at any time. Henry Samueli and Susan Samueli may be deemed to beneficially own any shares directly owned by H&S Investments. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:44 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | ConversionCommon Stock | 4,361,835 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009411 · doc4.xml · nonDerivative · entry 1 H&S INVESTMENTS I LP · CIK 0001219243 · 10% owner H&S VENTURES LLC · CIK 0001219242 · 10% owner SCHULMAN MICHAEL · CIK 0001219244 · 10% owner SAMUELI HENRY · CIK 0001201633 · 10% owner SAMUELI SUSAN · CIK 0001219241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,425,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held by H&S Investments I, L.P ("H&S Investments"), H&S Ventures, LLC ("H&S Ventures"), its general partner, and Michael Shulman, manager of H&S Ventures may be deemed to have voting and dispositive power with respect to the shares held. Henry Samueli and Susan Samueli are the non-managing members of H&S Ventures and each have the right to replace the managing member of H&S Ventures at any time. Henry Samueli and Susan Samueli may be deemed to beneficially own any shares directly owned by H&S Investments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.